Literature DB >> 24213221

Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways.

Yingmei Zhang1, Dongbo Xue, Xiaochun Wang, Ming Lu, Bo Gao, Xin Qiao.   

Abstract

The aim of this study was to identify agents that regulate autophagy. A total of 544 differentially expressed genes were screened from the intersection set of GSE2435 and GSE31040, which was obtained from the Gene Expression Omnibus database and 19 differentially expressed kinases were selected according to a 'protein kinase database'. Gene ontology‑biological process (GO-BP) enrichment analysis revealed that the 19 kinases were mainly associated with phosphorylation. The protein-protein interaction network exhibited 30 differentially expressed genes that interacted with BRAF, and GO-BP enrichment analysis showed the function of these genes were mainly involved in cell death and apoptosis. The kinase-kinase inhibitor regulatory network identified16 kinase inhibitors that specifically inhibited BRAF. Previous studies indicated that sorafenib is capable of regulating autophagy and regorafenib has also been reported; however, there have been no studies regarding the regulation of autophagy by afatinib, selumetinib, PD318088, axitinib, TAK-733, GDC-0980, GSK2126458, PLX-4720, AS703026, trametinib, GDC-0941 and PF-04217903. Thus, these kinase inhibitors are potential targets for further study on the regulation of autophagy in the future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24213221     DOI: 10.3892/mmr.2013.1781

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  12 in total

1.  Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial-mesenchymal transition.

Authors:  Chuntao Tian; Ying Liu; Lingfei Xue; Dong Zhang; Xiaotong Zhang; Jing Su; Jiaohong Chen; Xiangke Li; Liuxing Wang; Shunchang Jiao
Journal:  Open Life Sci       Date:  2022-06-15       Impact factor: 1.311

Review 2.  Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials.

Authors:  Bharat Goel; Anoop Kumar Tiwari; Rajeev Kumar Pandey; Akhand Pratap Singh; Sujeet Kumar; Abhishek Sinha; Shreyans K Jain; Arun Khattri
Journal:  Transl Oncol       Date:  2022-04-20       Impact factor: 4.803

Review 3.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

Review 4.  Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.

Authors:  Paulina Kozakiewicz; Ludmiła Grzybowska-Szatkowska
Journal:  Oncol Lett       Date:  2018-03-20       Impact factor: 2.967

5.  U0126 protects cells against oxidative stress independent of its function as a MEK inhibitor.

Authors:  Qunxiang Ong; Shunling Guo; Kai Zhang; Bianxiao Cui
Journal:  ACS Chem Neurosci       Date:  2015-01-06       Impact factor: 4.418

6.  Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience.

Authors:  Amr Shaaban Hanafy
Journal:  Springerplus       Date:  2016-09-29

Review 7.  Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.

Authors:  Danijel Galun; Tatjana Srdic-Rajic; Aleksandar Bogdanovic; Zlatibor Loncar; Marinko Zuvela
Journal:  J Hepatocell Carcinoma       Date:  2017-07-11

Review 8.  Ferroptosis and Cancer: Mitochondria Meet the "Iron Maiden" Cell Death.

Authors:  Anna Martina Battaglia; Roberta Chirillo; Ilenia Aversa; Alessandro Sacco; Francesco Costanzo; Flavia Biamonte
Journal:  Cells       Date:  2020-06-20       Impact factor: 6.600

Review 9.  Protein kinase inhibitors for acute leukemia.

Authors:  Yuan Ling; Qing Xie; Zikang Zhang; Hua Zhang
Journal:  Biomark Res       Date:  2018-02-13

10.  The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells.

Authors:  Li Wang; Qian Yang; Shaoyong Peng; Xiaoxia Liu
Journal:  Onco Targets Ther       Date:  2019-07-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.